Phaseline

Companies › Heron Therapeutics

Heron Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 5 registered trials: 4 Phase 4, 1 Phase 3; Other, Genitourinary.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Granisetron
Serotonin 3a (5-HT3a) receptor antagonist
HTR3APhase 4Chemotherapy-Induced Nausea and Vomiting (CINV); TMD; Nausea With Vomiting Chemotherapy-Induced; Nephrotoxicity–
HTX-011
Fixed-ratio combination of bupivacaine and meloxicam; bupivacaine is a local anesthetic th
TRPV1Phase 4Analgesia–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05109312HTX-011Phase 4AnalgesiaOtherJun 2024
NCT05434663GranisetronPhase 4Chemotherapy-Induced Nausea and Vomiting (CINV)OtherOct 2025
NCT07401745GranisetronPhase 4TMDOtherJul 2026
NCT04150614GranisetronPhase 4Nausea With Vomiting Chemotherapy-InducedOtherMar 2027
NCT03817970GranisetronPhase 3NephrotoxicityGenitourinarySep 2027

From the company's SEC filings

Complete response letters from FDA

Specialist investors

Held by 1 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

HTR3A (1) TRPV1 (1)

Companies with the same targets

RDC Clinical Takeda Valenta Pharm JSC

Companies built like this

Endo USA Inc., a Keenova Therapeutics Company Acer Therapeutics Shanghai Haiyan Pharmaceutical Technology Kaken Pharmaceutical Spine BioPharma

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.